SEROPROTECTION RATE OF HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE AND ASSOCIATED CLINICAL OUTCOMES AMONG NIGERIAN CHILDREN AGED 6 TO 23 MONTHS.

Autor:	Ozhe SI; Department of Paediatrics, Dalhatu Araf Specialist Hospital, Lafia, Nasarawa State. Email: sunozhe@gmail.com., Shwe DD; Department of Paediatrics, University of Jos/Jos University Teaching Hospital, Jos, Plateau State., Yilgwan CS; Department of Paediatrics, University of Jos/Jos University Teaching Hospital, Jos, Plateau State., Isaac JA; Department of Pharmaceutical and Raw Materials Development, National Institute for. Pharmaceutical Research and Development, Abuja, Nigeria., Ehizibolo DO; Infectious and Transboundary Animal Diseases Department, National Veterinary Research Institute, Vom, Plateau State., Luka PD; Biotechnology Centre, National Veterinary Research Institute, Vom, Plateau State., Ebisike KJ; Department of Paediatrics, Federal Teaching Hospital/Gombe State University, Gombe, Gombe State., Ocheke IE; Department of Paediatrics, University of Jos/Jos University Teaching Hospital, Jos, Plateau State.
Jazyk:	angličtina
Zdroj:	West African journal of medicine [West Afr J Med] 2023 Dec 04; Vol. 40 (12 Suppl 1), pp. S33.
Abstrakt:	Introduction: Haemophilus influenzae type b (Hib) causes invasive infections almost exclusively in under- fives with those aged 6-23 months being the most vulnerable. In Nigeria, it is estimated to cause nearly 400,000 annual infections and another 30,000 under-five mortality attributable to pneumonia and meningitis alone. The Hib Conjugate Vaccine (HCV) is in widespread use to combat these devastating infections. Data on its impact in Nigeria is grossly scanty. This study evaluated the seroprotection rates (SPR) of HCV and associated clinical outcomes among children aged 6-23 months in Obi L.G.A. of Nasarawa State, Nigeria. Methods: A cross-sectional study of 267 children aged 6-23 months who had completed three doses of HCV. They were enrolled via a two-staged household-level cluster sampling. Relevant sociodemographic and clinical data were obtained using structured questionnaires and serum samples collected were analysed serologically for antipolyribosylribitol phosphate (anti-PRP) antibodies using ELISA. Results: The overall SPRs against invasive Hib disease and Hib nasopharyngeal colonization were 74.2% and 26.2%, respectively. The overall geometric mean titre (GMT) of anti-PRP was 1.85 µg/mL (95%CI: 1.60-2.14) and across age groups, GMTs were >1 µg/mL-the threshold for long-term protection against invasive Hib disease. Rates/duration of healthcare admissions and average episodes of probable Hib disease syndromes were lower in seroprotected but not statistically different from non-seroprotected children. Conclusion: The demonstrated anti-PRP titres and Seroprotection Rates infer a very good HCV efficacy in Nigerian children. The lack of significant difference in clinical outcomes may be attributable to nonspecificity. (Copyright © 2023 by West African Journal of Medicine.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu